

Natco Pharma Limited

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243 CIN: L24230TG1981PLC003201, www.natcopharma.co.in

5th February, 2021

Corporate Relationship Department M/s. BSE Ltd.
Dalal Street, Fort
Mumbai 400 001.

Manager – Listing M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex Bandra (E) <u>Mumbai 400 051</u>

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir,

Please find enclose herewith the Press Release for your information.

Thanking you,

Yours faithfully,

For NATCO Pharma Limited

M. Adinarayana

Morange

Company Secretary &

Vice President (Legal and Corp. Affairs)

Encl: a.a.



Natco Pharma Limited

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243 CIN: L24230TG1981PLC003201, www.natcopharma.co.in

PR/13/2021

Press Release

NATCO receives approval for Chlorantraniliprole (CTPR)-1st key product of Crop Health Sciences Division

Hyderabad, India, February 5th, 2021

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce its registration approval given by Central Insecticide Board & Registration Committee (CIB&RC) recorded in its Minutes of the 425th Meeting held on 25.01.2021, for indigenous manufacture of *Chlorantraniliprole (CTPR) Technical 93.00% w/w min.* under Section 9(3) of Insecticides Act, 1968. NATCO would be the 1st indigenous manufacturer of this technical product.

CTPR technical is formulated into broad-spectrum insecticides used in several crops for better pest management. NATCO hopes to bring products based on CTPR shortly that would be affordable and accessible to farmers across India.

CTPR is an active ingredient used in products commercialized by FMC under brands Coragen® & Ferterra®. The sales generated from CTPR containing products in India, inclusive of third-party marketing companies, as per declaration given by FMC was estimated to be INR 1540 crores in 2016. NATCO believes the current market size to be over INR 2000 crores. NATCO has a pending litigation against FMC for declaration of freedom to use of CTPR.

Forwarded for favor of publication
For NATCO Pharma Limited

M. Adinarayana

Company Secretary & Vice President (Legal and Corp Affairs)